CA2390632A1 - Methods of treating short stature disorders related to the short stature homeobox-containing (shox) gene - Google Patents
Methods of treating short stature disorders related to the short stature homeobox-containing (shox) gene Download PDFInfo
- Publication number
- CA2390632A1 CA2390632A1 CA002390632A CA2390632A CA2390632A1 CA 2390632 A1 CA2390632 A1 CA 2390632A1 CA 002390632 A CA002390632 A CA 002390632A CA 2390632 A CA2390632 A CA 2390632A CA 2390632 A1 CA2390632 A1 CA 2390632A1
- Authority
- CA
- Canada
- Prior art keywords
- growth hormone
- shox
- subjects
- disorder
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 84
- 208000020221 Short stature Diseases 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title abstract description 25
- 108090000623 proteins and genes Proteins 0.000 title abstract description 20
- 102000048489 Short Stature Homeobox Human genes 0.000 title abstract description 5
- 108700025071 Short Stature Homeobox Proteins 0.000 title abstract description 5
- 208000035475 disorder Diseases 0.000 claims abstract description 82
- 102000018997 Growth Hormone Human genes 0.000 claims abstract description 77
- 108010051696 Growth Hormone Proteins 0.000 claims abstract description 77
- 239000000122 growth hormone Substances 0.000 claims abstract description 77
- 208000026928 Turner syndrome Diseases 0.000 claims abstract description 73
- 108010000521 Human Growth Hormone Proteins 0.000 claims abstract description 58
- 102000002265 Human Growth Hormone Human genes 0.000 claims abstract description 58
- 239000000854 Human Growth Hormone Substances 0.000 claims abstract description 57
- 101150012871 SHOX gene Proteins 0.000 claims abstract description 43
- 241000282414 Homo sapiens Species 0.000 claims abstract description 15
- 238000011282 treatment Methods 0.000 claims description 51
- 230000012010 growth Effects 0.000 claims description 42
- 238000002560 therapeutic procedure Methods 0.000 claims description 23
- 230000001154 acute effect Effects 0.000 claims description 14
- 239000005022 packaging material Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 11
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 230000037396 body weight Effects 0.000 claims 4
- 238000011269 treatment regimen Methods 0.000 claims 1
- 210000001766 X chromosome Anatomy 0.000 abstract description 12
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 210000002593 Y chromosome Anatomy 0.000 abstract description 5
- 230000007812 deficiency Effects 0.000 abstract description 5
- 229960004532 somatropin Drugs 0.000 description 35
- 238000004458 analytical method Methods 0.000 description 32
- 238000012216 screening Methods 0.000 description 16
- 201000001934 Leri-Weill dyschondrosteosis Diseases 0.000 description 14
- 238000012217 deletion Methods 0.000 description 14
- 230000035772 mutation Effects 0.000 description 14
- 206010071437 Dyschondrosteosis Diseases 0.000 description 13
- 230000037430 deletion Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000000203 mixture Substances 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 210000000988 bone and bone Anatomy 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 7
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 7
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 7
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 7
- 230000005856 abnormality Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000009578 growth hormone therapy Methods 0.000 description 7
- 230000007547 defect Effects 0.000 description 6
- 206010056438 Growth hormone deficiency Diseases 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 206010007700 Carpus curvus Diseases 0.000 description 3
- 206010053759 Growth retardation Diseases 0.000 description 3
- 108700005087 Homeobox Genes Proteins 0.000 description 3
- 208000009632 Madelung deformity Diseases 0.000 description 3
- 206010072610 Skeletal dysplasia Diseases 0.000 description 3
- 210000000245 forearm Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000001699 lower leg Anatomy 0.000 description 3
- 238000013179 statistical model Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 210000000707 wrist Anatomy 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 208000008063 Langer mesomelic dysplasia Diseases 0.000 description 2
- 208000006302 Laron syndrome Diseases 0.000 description 2
- 201000007908 Ocular Albinism Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008195 breast development Effects 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000011272 imaginal disc-derived genitalia development Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 210000003765 sex chromosome Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000766026 Coregonus nasus Species 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000016857 Growth hormone insensitivity syndrome Diseases 0.000 description 1
- 206010020046 High arched palate Diseases 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010023204 Joint dislocation Diseases 0.000 description 1
- 206010025282 Lymphoedema Diseases 0.000 description 1
- 108010013127 Met-human growth hormone Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027543 Micrognathia Diseases 0.000 description 1
- 208000002598 Micrognathism Diseases 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 102100032341 PCNA-interacting partner Human genes 0.000 description 1
- 101710196737 PCNA-interacting partner Proteins 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 241001227561 Valgus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 206010016165 failure to thrive Diseases 0.000 description 1
- 210000002082 fibula Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000010437 gem Substances 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 208000002566 gonadal dysgenesis Diseases 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 210000004090 human X chromosome Anatomy 0.000 description 1
- 230000001096 hypoplastic effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000002502 lymphedema Diseases 0.000 description 1
- 210000004373 mandible Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 208000011426 mesomelic dysplasia Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008722 morphological abnormality Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000018406 regulation of metabolic process Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 206010039722 scoliosis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000008771 sex reversal Effects 0.000 description 1
- 231100001055 skeletal defect Toxicity 0.000 description 1
- 210000002356 skeleton Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009576 somatic growth Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 210000000623 ulna Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16434199P | 1999-11-09 | 1999-11-09 | |
| US60/164,341 | 1999-11-09 | ||
| PCT/IB2000/001612 WO2001034181A2 (en) | 1999-11-09 | 2000-11-08 | Methods of treating short stature disorders related to the short stature homeobox-containing (shox) gene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2390632A1 true CA2390632A1 (en) | 2001-05-17 |
Family
ID=22594056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002390632A Abandoned CA2390632A1 (en) | 1999-11-09 | 2000-11-08 | Methods of treating short stature disorders related to the short stature homeobox-containing (shox) gene |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1227832A2 (de) |
| JP (1) | JP2003513934A (de) |
| AU (1) | AU1292201A (de) |
| CA (1) | CA2390632A1 (de) |
| CZ (1) | CZ20021718A3 (de) |
| HU (1) | HUP0204116A3 (de) |
| PL (1) | PL357471A1 (de) |
| WO (1) | WO2001034181A2 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060172929A1 (en) * | 2003-01-13 | 2006-08-03 | Gudrun Rappold-Hoerbrand | Use of natriuretic peptides for the treatment of stature disorders related to the shox gene |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824642A (en) * | 1994-04-07 | 1998-10-20 | Genentech, Inc. | Treatment of partial growth hormone insensitivity syndrome |
| US5631225A (en) * | 1994-10-13 | 1997-05-20 | Novo Nordisk A/S | Pharmaceutical formulation |
-
2000
- 2000-11-08 HU HU0204116A patent/HUP0204116A3/hu unknown
- 2000-11-08 CA CA002390632A patent/CA2390632A1/en not_active Abandoned
- 2000-11-08 AU AU12922/01A patent/AU1292201A/en not_active Abandoned
- 2000-11-08 PL PL00357471A patent/PL357471A1/xx not_active Application Discontinuation
- 2000-11-08 JP JP2001536178A patent/JP2003513934A/ja active Pending
- 2000-11-08 CZ CZ20021718A patent/CZ20021718A3/cs unknown
- 2000-11-08 EP EP00974708A patent/EP1227832A2/de not_active Ceased
- 2000-11-08 WO PCT/IB2000/001612 patent/WO2001034181A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU1292201A (en) | 2001-06-06 |
| PL357471A1 (en) | 2004-07-26 |
| WO2001034181A3 (en) | 2001-12-06 |
| CZ20021718A3 (cs) | 2002-11-13 |
| WO2001034181A2 (en) | 2001-05-17 |
| EP1227832A2 (de) | 2002-08-07 |
| HUP0204116A2 (hu) | 2003-03-28 |
| HUP0204116A3 (en) | 2005-07-28 |
| JP2003513934A (ja) | 2003-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0436469B1 (de) | Zusammensetzung und Verfahren für die Behandlung von Osteoporose bei Säugetieren | |
| US20070014818A1 (en) | Liquid formulations with high concentration of human growth hormone (HGH) comprising 1,2-propylene glycol | |
| Reeve et al. | Preliminary trial of low doses of human parathyroid hormone 1–34 peptide in treatment of osteoporosis | |
| JP3771280B2 (ja) | オステオポローシスの治療方法およびそのための組成物 | |
| Romer et al. | Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope® in the treatment of growth hormone deficient children: results of a phase III study | |
| US8440616B2 (en) | Methods for treatment of insulin-like growth factor-1 deficiency | |
| US20070065469A1 (en) | Liquid formulations with high concentration of human growth hormone (high) comprising glycine | |
| JP2016508125A (ja) | ヒト成長ホルモンおよびアルブミンの融合、その製剤および使用 | |
| Phillips et al. | Nutrition and somatomedin. XIV. Altered levels of somatomedins and somatomedin inhibitors in rats with streptozotocin-induced diabetes | |
| Schneider et al. | The anabolic effects of vitamin D-binding protein-macrophage activating factor (DBP-MAF) and a novel small peptide on bone | |
| CA2390632A1 (en) | Methods of treating short stature disorders related to the short stature homeobox-containing (shox) gene | |
| EP1755637B1 (de) | Verfahren zur prävention oder behandlung von knochenerkrankungen | |
| US20070066519A1 (en) | Use of human growth hormone in multiple system atrophy | |
| STEINER et al. | Rare dwarfism with chronic hypoglycemia and convulsions | |
| Şen Küçük | Reversible Injection-Site Lipoatrophy Induced by Long-Acting Growth Hormone (Somatrogon) in Pediatric Growth Hormone Deficiency: A Case Series | |
| Standard et al. | PrTEVA-TERIPARATIDE INJECTION | |
| AU2023314508A1 (en) | Methods for improving muscle mass, strength, or function with a combination of testosterone and growth hormone | |
| Farías et al. | Relative bioavailability between two teriparatide formulations in healthy volunteers | |
| HK1178454A (en) | Methods for treatment of insulin-like growth factor-1 (igf-1) deficiency | |
| TW201318636A (zh) | 用於治療膽道狹窄或／及阻塞之ｇｌｐ－１促效劑 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |